[1] Kessenich CR. Cyclo-oxygenase 2 inhibitors: an important new drug classification [J]. Pain Manag Nurs, 2001, 2 (1): 13-18. [2] Patrono C, Coller B, Dalen J E, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects [J]. Chest, 1998, 114 (5 Suppl): 470-488. [3] Catella2Lawson F. Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects [J]. Neurology, 2001, 57 (5 Suppl 2): 5-7. [4] Cleland LG, James MJ, Stamp LK, et al. COX-2 inhibition and thrombotic tendency: a need for surveillance [J]. Med J Aust, 2001, 175 (4): 214-217. [5] Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors [J]. J Am Med Assoc, 2001, 286 (8): 954-959. [6] Josefson D. FDA warns Merck over its promotion of rofecoxib [J]. BMJ, 2001, 323 (7316): 767. |